chrX-139541114-G-A

Variant summary

Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PP3PP1PP4_ModeratePS4PM1

This summary comes from the ClinGen Evidence Repository: The c.316G>A (p.Gly106Ser) variant affects one of the functional domains (aa 93-129; EGF-like 1 domain) in the F9 protein, meeting the PM1 criteria. This missense variant has a REVEL score of 0.905(>0.6), meeting the PP3 criteria. It is reported at an MAF of 0.00002441 (5/204867 alleles) in the overall population in gnomAD v2.1.1, with 3 hemizygotes; however BS1 criteria of MAF >=0.0000278 is not met. Over 60 patients with mild and moderate hemophilia B are reported in the literature meeting PS4_Very strong and PP4_Moderate criteria (PMID:22103590, 29296726). In summary, the clinical significance of this variant is pathogenic. ACMG/AMP criteria applied, as specified by the Coagulation Factor Deficiency Variant Curation Expert Panel for F9: PS4_Very strong, PM1, PP4_Moderate, PP3. LINK:https://erepo.genome.network/evrepo/ui/classification/CA255329/MONDO:0010604/080

Frequency

Genomes: 𝑓 0.000036 ( 0 hom., 2 hem., cov: 23)
Exomes 𝑓: 0.0000074 ( 0 hom. 3 hem. )

Consequence

F9
NM_000133.4 missense

Scores

9
6
2

Clinical Significance

Pathogenic reviewed by expert panel P:10

Conservation

PhyloP100: 8.98
Variant links:
Genes affected
F9 (HGNC:3551): (coagulation factor IX) This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing. [provided by RefSeq, Sep 2015]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 10 ACMG points.

PS4
For more information check the summary or visit ClinGen Evidence Repository.
PM1
For more information check the summary or visit ClinGen Evidence Repository.
PP1
For more information check the summary or visit ClinGen Evidence Repository.
PP3
For more information check the summary or visit ClinGen Evidence Repository.
PP4
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
F9NM_000133.4 linkuse as main transcriptc.316G>A p.Gly106Ser missense_variant 4/8 ENST00000218099.7 NP_000124.1
F9XM_005262397.5 linkuse as main transcriptc.316G>A p.Gly106Ser missense_variant 4/7 XP_005262454.1
F9NM_001313913.2 linkuse as main transcriptc.277+3728G>A intron_variant NP_001300842.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
F9ENST00000218099.7 linkuse as main transcriptc.316G>A p.Gly106Ser missense_variant 4/81 NM_000133.4 ENSP00000218099 P1P00740-1
F9ENST00000394090.2 linkuse as main transcriptc.277+3728G>A intron_variant 1 ENSP00000377650 P00740-2
F9ENST00000479617.2 linkuse as main transcriptn.269G>A non_coding_transcript_exon_variant 3/45

Frequencies

GnomAD3 genomes
AF:
0.0000359
AC:
4
AN:
111504
Hom.:
0
Cov.:
23
AF XY:
0.0000593
AC XY:
2
AN XY:
33710
show subpopulations
Gnomad AFR
AF:
0.0000326
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000956
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.000166
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000188
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000109
AC:
2
AN:
183001
Hom.:
0
AF XY:
0.0000296
AC XY:
2
AN XY:
67603
show subpopulations
Gnomad AFR exome
AF:
0.0000760
Gnomad AMR exome
AF:
0.0000365
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000736
AC:
8
AN:
1087481
Hom.:
0
Cov.:
28
AF XY:
0.00000845
AC XY:
3
AN XY:
355229
show subpopulations
Gnomad4 AFR exome
AF:
0.0000384
Gnomad4 AMR exome
AF:
0.0000287
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000186
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000599
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.0000359
AC:
4
AN:
111504
Hom.:
0
Cov.:
23
AF XY:
0.0000593
AC XY:
2
AN XY:
33710
show subpopulations
Gnomad4 AFR
AF:
0.0000326
Gnomad4 AMR
AF:
0.0000956
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.000166
Gnomad4 NFE
AF:
0.0000188
Gnomad4 OTH
AF:
0.00
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000149
AC:
1
EpiCase
AF:
0.0000546
EpiControl
AF:
0.00

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:10
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Hereditary factor IX deficiency disease Pathogenic:4
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Sep 16, 2020- -
Pathogenic, no assertion criteria providedliterature onlyOMIMJul 25, 1989- -
Pathogenic, reviewed by expert panelcurationClinGen Coagulation Factor Deficiency Variant Curation Expert Panel, ClingenFeb 09, 2024The c.316G>A (p.Gly106Ser) variant affects one of the functional domains (aa 93-129; EGF-like 1 domain) in the F9 protein, meeting the PM1 criteria. This missense variant has a REVEL score of 0.905(>0.6), meeting the PP3 criteria. It is reported at an MAF of 0.00002441 (5/204867 alleles) in the overall population in gnomAD v2.1.1, with 3 hemizygotes; however BS1 criteria of MAF >=0.0000278 is not met. Over 60 patients with mild and moderate hemophilia B are reported in the literature meeting PS4_Very strong and PP4_Moderate criteria (PMID: 22103590, 29296726). In summary, the clinical significance of this variant is pathogenic. ACMG/AMP criteria applied, as specified by the Coagulation Factor Deficiency Variant Curation Expert Panel for F9: PS4_Very strong, PM1, PP4_Moderate, PP3. -
Pathogenic, criteria provided, single submitterclinical testingGenetics and Molecular Pathology, SA PathologyJul 27, 2023The F9 c.316G>A missense variant has been classified as Pathogenic (PS4_Strong, PP3, PS3_Moderate, PP1_Moderate, PP4). The c.316G>A variant is a single nucleotide change in exon 4/8 of the F9 gene, which is predicted to change the amino acid glycine at position 106 in the protein to serine. This variant is in gnomAD at very low frequency (0.003%, allele count 4/111504, 2 hemizygous) and has been reported in numerous affected individuals with mild haemophilia B (PMID:22639855, 35842956, and 2472424) (PS4_strong). Note that this variant has been previously reported in the literature as p.Gly60Ser. Computational data predicts a deleterious effect (PP3). This variant is located in the functional cbEGF domain and has been predicted to affect protein folding (PMID: 9525872) (PS3_moderate). The variant has been shown to segregate with disease in 2 patients and a proband from 2 families (PMID: 2472424, 3651597) and has been reported to have been found in at least 5 generations (PP1_Moderate). The patient's family history and FIX bioassay levels are consistent with the specific gene aetiology (PP4). This variant is a missense change at an amino acid residue where different missense changes have been seen before: p.Gly106Arg (CM940467), p.Gly106Asp (CM940465), p.Gly106Cys (CM960576). This variant has been reported in dbSNP (rs137852233), HGMD as disease causing (CM940466) and in ClinVar as pathogenic (ClinVar variant ID: 10579). -
not provided Pathogenic:2
Pathogenic, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesSep 17, 2021The F9 c.316G>A; p.Gly106Ser variant (rs1378522233), also known as Gly60Ser or FIX Durham, is reported in numerous patients diagnosed with mild hemophilia B (Chavali 2009, Chen 1989, Denton 1988, Poort 1989, Factor IX Variant Database and references therein). This variant is reported as pathogenic in ClinVar (Variation ID: 10579) and is found in the general population at a low overall allele frequency of 0.003% (5/204867 alleles, including 3 hemizygotes) in the Genome Aggregation Database. The glycine at codon 106 is highly conserved and located in the calcium-binding EGF-like domain. Structural analyses demonstrate that the variant increases the likelihood of defective folding in the EGF-like domain of the protein (Whiteman 1998). Additionally, other amino acid substitutions at this codon (Arg, Cys, and Asp) have been reported in individuals with hemophilia B and are considered disease-causing (Factor IX Variant Database and references therein). Based on available information, the p.Gly106Ser variant is considered to be pathogenic. References: Factor IX Variant Database: http://f9-db.eahad.org/ Chavali S et al. Hemophilia B is a quasi-quantitative condition with certain mutations showing phenotypic plasticity. Genomics. 2009 Dec;94(6):433-7. Chen SH et al. Three point mutations in the factor IX genes of five hemophilia B patients. Identification strategy using localization by altered epitopes in their hemophilic proteins. J Clin Invest. 1989 Jul;84(1):113-8. Denton PH et al. Hemophilia B Durham: a mutation in the first EGF-like domain of factor IX that is characterized by polymerase chain reaction. Blood. 1988 Oct;72(4):1407-11. Poort SR et al. A Dutch pedigree with mild hemophilia B with a missense mutation in the first EGF domain (factor IXOud en Nieuw Gastel). Nucleic Acids Res. 1989 Jul 25;17(14):5869. Whiteman P et al. A Gly --> Ser change causes defective folding in vitro of calcium-binding epidermal growth factor-like domains from factor IX and fibrillin-1. J Biol Chem. 1998 Apr 3;273(14):7807-13. -
Pathogenic, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicDec 29, 2022PP3, PP5, PM1_supporting, PM5, PS3, PS4_moderate -
F9-related disorder Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesFeb 21, 2024The F9 c.316G>A variant is predicted to result in the amino acid substitution p.Gly106Ser. This variant, also referred to as Hemophilia B Durham, has been reported previously in many patients to be causative for Hemophilia B (Denton et al. 1988. PubMed ID: 3262389; Tengguo et al. 2014. PubMed ID: 24375831; Factor IX Gene (F9) Variant Database: http://www.factorix.org/). Several other missense changes at this same position (p.Gly106Cys, p.Gly106Arg, and p.Gly106Asp) have also been reported to be causative for Hemophilia B (Factor IX Gene (F9) Variant Database: http://www.factorix.org/). This variant is reported in 0.011% of alleles in individuals of African descent in gnomAD. The c.316G>A (p.Gly106Ser) variant is interpreted as pathogenic. -
Hereditary factor IX deficiency disease;C2749016:Thrombophilia, X-linked, due to factor 9 defect Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 25, 2024This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 106 of the F9 protein (p.Gly106Ser). This variant is present in population databases (rs137852233, gnomAD 0.01%). This missense change has been observed in individuals with mild hemophilia B (PMID: 2472424, 19699296, 22639855). It has also been observed to segregate with disease in related individuals. This variant is also known as Gly60Ser, 10430G>A, and FIX Durham. ClinVar contains an entry for this variant (Variation ID: 10579). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt F9 protein function with a negative predictive value of 80%. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on F9 function (PMID: 9525872). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Thrombophilia, X-linked, due to factor 9 defect Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingMendelicsMay 04, 2022- -
Hereditary factor IX deficiency disease;C2749016:Thrombophilia, X-linked, due to factor 9 defect;C5393318:Warfarin sensitivity, X-linked Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsSep 18, 2021- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.18
BayesDel_addAF
Pathogenic
0.55
D
BayesDel_noAF
Pathogenic
0.74
CADD
Uncertain
26
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.93
D
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.96
D
M_CAP
Pathogenic
0.94
D
MetaRNN
Pathogenic
0.97
D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Uncertain
2.9
M
MutationTaster
Benign
1.0
A;A
PrimateAI
Uncertain
0.49
T
PROVEAN
Pathogenic
-4.7
D
REVEL
Pathogenic
0.91
Sift
Uncertain
0.0040
D
Sift4G
Uncertain
0.0070
D
Polyphen
1.0
D
Vest4
0.81
MVP
1.0
MPC
2.9
ClinPred
0.97
D
GERP RS
5.8
Varity_R
0.92
gMVP
1.0

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.12
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs137852233; hg19: chrX-138623273; COSMIC: COSV54382023; COSMIC: COSV54382023; API